Synvista initiates dosing in Phase II psoriasis trial

The trial is planned to be a 28-day multi-center, randomized, double-blind, placebo controlled study to assess the efficacy of topical SYI-2074, applied twice daily, for the treatment of chronic, mild-to-moderate plaque psoriasis in adults. The trial is being conducted in three centers in Israel.

Noah Berkowitz, president and CEO of Synvista Therapeutics, said: “We are very excited to begin Phase II clinical trials on SYI-2074 for psoriasis. We believe that there is immense potential to expand the scope of treatment modalities for psoriasis following this trial and look forward to reporting results in the first quarter of 2009.”